Uncategorised - European Medical Journal

CKD Severity Linked to Increased Risk of Cognitive Impairment

Greater chronic kidney disease severity, particularly proteinuria, is linked to increased risk of cognitive impairment, a large cohort study finds.

Type 1 Diabetes Tied to Threefold Increase in Dementia Risk

Adults above 50 with Type 1 diabetes are nearly three times as likely to develop incident dementia as those without. Read more.

Childhood Trauma Tied to Increased Dementia Risk

Abuse, neglect, and socioeconomic deprivation in childhood have been linked to faster ageing-related changes, including an increased risk of dementia.

Low Testosterone Tied to Extreme Prostate Cancer Progression

Patients under active surveillance for prostate cancer with low testosterone are more likely to experience ‘extreme’ disease progression, a 2026 study has found.

Liquid Biopsy Accelerates Diagnosis of Burkitt’s Lymphoma

Liquid biopsy significantly reduced the median turnaround time from 46.8 days to just 6.5 days, offering a substantial improvement in diagnostic efficiency.

Model Improves Detection of Sessile Serrated Lesions

New nomogram integrates clinical and endoscopic features to distinguish high-risk colorectal lesions from hyperplastic polyps.

24 Mar 2026

Value of Achieving Minimal Disease Activity in Atopic Dermatitis

AD is a common, chronic inflammatory skin disease with a significant impact on patients’ lives.1 As a heterogeneous disease, AD has…

Women holding a clipboard

ABPI calls for NHS data use to boost trial recruitment

The NHS is sitting on a gold mine of patient data that could, in the ABPI’s view, help rescue the UK’s faltering clinical trials sector.

Scientist standing behind a microscope while holding up a vial and a pipette.

Nanotechnology Therapeutics Reframe Autoimmune Disease Care

Nanotechnology therapeutics may improve autoimmune disease treatment by enhancing targeting, lowering toxicity, and enabling immune modulation.

Hideki Garren on rethinking multiple sclerosis care

Hideki Garren explores how our understanding of MS is evolving, the challenge of measuring disease progression and what the future holds.